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Results: 14,764 pts were seen with a primary diagnosis of NSCLC. 
5,114 received initial treatment at MDACC. 1,925 had surgery alone or 
with a multidisciplinary approach. LTS was achieved in 294 of 3,189 
(9.2%) who had only radiation therapy, chemotherapy or some combi-
nation of both. Median survival for LTS was 5.2 years. Stages: IA=29 
(9.9%), IB=18 (6.1%), IIA=4 (1.4%), IIB=2 (0.7%), IIIA=56 (19.0%), 
IIIB=98 (33.3%), and STAGE IV=87 (29.6%).
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IA 29 21 6  2 29   
IB 18 10 7  1 16 1 1
IIA 4 3 1   1  3
IIB 2 2    2   
IIIA 56 42 5 1 8 9 3 44
IIIB 98 63 9 4 22 19 9 70
IV 87 48 19 4 8 15 60 12
III & IV 
Only 241 153 33 9 38 XXXXX XXXXX XXXXX
All 
Patients 294 189 47 9 41 91 73 130
Upper lobe lesions made up 189/294 (64.3%) LTS cases versus 47 
lower lobe lesions (16.0%) with 9 middle lobe or lingula. The re-
mainder were central. The ratio of upper to lower lobe lesions was 4:1 
- dramatically different from the usual 2:1 ratio (p=0.0002). The ratio is 
even more pronounced taking Stages III & IV only. 
Conclusions: Upper lobe lesions - especially RUL - appear signiﬁ-
cantly more common than lower lobe lesions in LTS of NSCLC treated 
without surgery. 
Discussion: Prognostic models of NSCLC will be improved by includ-
ing location of the primary tumor. 
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Background: To investigate the role of WPC and concurrent TR as 
neoadjuvant therapy before S for the patients with pN2-stage IIIA 
NSCLC.
Methods: Patients with pN2 and operable stage IIIA NSCLC were 
eligible. Six weekly chemotherapies with paclitaxel (50mg/m2)/cispla-
tin (20mg/m2) were given with concurrent TR (1.8Gy/day x 5/week, 45 
Gy) during 5 weeks. Chest CT, FDG-PET scan were checked before 
and 3 weeks after chemoradiation. S was performed at least 4 weeks 
after concurrent chemoradiation. For the patients without clearing pN2 
nodes or with pT3 after S, boost radiation (20Gy) was given.
Results: From January 2002 to February 2006, 41 patients were 
enrolled. The median follow up time was 27.2 months: gender (male: 
female, 31: 10), age (median 56, 44-67 years old). Of them, 35 patients 
underwent S. Three patients showed brain metastasis during chemo-
radiation (but one patient underwent S after gamma knife surgery of 
single brain metastasis). Two patients refused S after chemoradiation. 
One patient showed severe radiation pneumonitis and was not ﬁt for S. 
One patient showed lung to lung metastases before S. Eighteen patients 
(43.9%) showed pN0-1, and 9 patients (22.0%) showed pathologic 
complete remission (CR). Four year progression free survival and 
overall survival were 44.0% (median 21.2 months) and 42.6% (median 
35.4 months). In univariate analysis clearing N2 node and pahologic 
CR after S were the facts that could predict long term survival. Grade 3 
or 4 toxicities during WPC included anemia (7.3%), neutropenia (6%), 
thrombocytopenia (2.4%), Hypersensitivity reaction (2.4%), radiation 
pneumonitis (12.2%), and radiation esophagitis (7.3%). There was no 
treatment-related death.
Conclusions: WPC with concurrent TR followed by S for pN2 stage 
IIIA NSCLC was feasible. Clearing N2 nodes or pathologic CR after S 
were the facts of long tern survival. 
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Background: The prognosis of patients with stage III non-small cell 
lung cancer (NSCLC) who achieved pathological complete response or 
downstaging following neoadjuvant chemotherapy is better than those 
with residual metastatic lymph node (LN). However, the prognostic 
signiﬁcance of the number of residual metastatic LNs remains unclear. 
Methods: From January 2001 to January 2006, 42 consecutive patients 
with stage IIIAN2 (22 patients) and IIIB without pleural effusion (20 
patients) were treated with neoadjuvant chemotherapy. Thirty four of 
42 patients were pathologically staged by mediastinoscopy. Neoadju-
vant chemotherapy consisted of 3 cycles of platinum based doublet (21 
patients with gemcitabine, 15 with paclitaxel, and 6 with docetaxel). 
Results: After neoadjuvant chemotherapy, pathological complete 
response and downstaging was achieved in one patient and 24 patients, 
respectively. No pathological LN metastasis was present in 9 patients 
(21.4%), and LN metastasis was present in 33 patients (78.6%). With a 
median follow up of 23 months, the 2-year disease free survival (DFS) 
rate of patients without residual LN metastasis was statistically better 
than that of patients with residual LN metastasis (46% and 18% in 
patients with residual LN, p=0.03). Among 33 patients with residual 
LN metastasis, age (p=0.01), pathological downstaging (p=0.09) and 
number of residual metastatic LNs (median 14 months in LN ≤4 vs 
median 5 months in LN ≥5; p=0.01) were signiﬁcant predictors of DFS 
in univariate analysis. In multivariate analysis, number of residual 
metastatic LNs was an independent predictor of DFS among patients 
with residual LN metastasis, irrespective of pathological downstaging.
Conclusion: The number of residual metastatic lymph nodes follow-
ing neoadjuvant chemotharpy is an independent predictor of DFS in 
patients with stage III NSCLC.
